13 | HS&M JANUARY/FEBRUARY 2016
“The heart of innovation is differentiated solutions for
the patient.” This will form one of the key planks of
it is not exactly clear to anyone how the new business
models will evolve. “What we know, I think, is that the
patient will become more central,” he says.
Since there is pressure on resources, pharma has
to ensure that investment is geared towards really
creating a return for the different stakeholders
Alignment not conflict
various stakeholders to be aligned rather than
conflicting. “That’s the reason why for me, focusing
on the patients is the starting point of any type of
business model thinking because, at the end of the day,
if we can ensure and demonstrate the value created,
then it’s easier to align the other stakeholders towards
environment. “We are far from being in a leading
position in immunology but we are progressing,” he
adds. “The second key component is the pipeline,
because I do think that in this industry and for us in
particular, success will come through innovations and
of revenue into R&D.
“We have a good pipeline and we have continued to
progress in the early stage pipeline,” Tellier continues.
“We currently have several products starting in Phase
In the short term, Tellier is happy delivering on
growth and continuing to invest in the pipeline “in
order to continue to deliver value to the patient”.
The ability of patients to have greater influence over